[go: up one dir, main page]

PE20060712A1 - Compuestos derivados de quinolinamina como moduladores del receptor de quimioquina - Google Patents

Compuestos derivados de quinolinamina como moduladores del receptor de quimioquina

Info

Publication number
PE20060712A1
PE20060712A1 PE2005001007A PE2005001007A PE20060712A1 PE 20060712 A1 PE20060712 A1 PE 20060712A1 PE 2005001007 A PE2005001007 A PE 2005001007A PE 2005001007 A PE2005001007 A PE 2005001007A PE 20060712 A1 PE20060712 A1 PE 20060712A1
Authority
PE
Peru
Prior art keywords
quinolinamine
alkyl
methyl
haloalkyl
alkenyl
Prior art date
Application number
PE2005001007A
Other languages
English (en)
Inventor
Kristjan Gudmundsson
Sharon Davis Boggs
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of PE20060712A1 publication Critical patent/PE20060712A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE QUINOLINAMINA DE FORMULA I, DONDE t ES 0, 1 O 2; R ES H, ALQUILO, ALQUINILO, ENTRE OTROS; R1 ES HALOGENO, HALOALQUILO, ALQUENILO, ENTRE OTROS; n ES 0, 1 0 2; R2 ES H, ALQUILO, HALOALQUILO, ENTRE OTROS; R3 ES H, ALQUILO, CICLOALQUILO, ENTRE OTROS; R4 ES HALOGENO, HALOALQUILO, ALQUENILO, ENTRE OTROS; m ES 0, 1 O 2; R5 ES H, ALQUILO, ALQUENILO, ENTRE OTROS; p ES 0 O 1; Y ES NR10, O, C(O), C(O)O, ENTRE OTROS; X ES N(R10)2, RaN(R10)2, ENTRE OTROS; Ra ES ALQUILENO SUSTITUIDO CON OH, O, ALQUILO, ENTRE OTROS; R10 ES H, ALQUILO, CICLOALQUILO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-METIL-N-{[5-(4-METIL-1-PIPERAZINIL)IMIDAZO[1,2-a]PIRIDIN-2-IL]METIL}-5,6,7,8-TETRAHIDRO-8-QUINOLINAMINA, N-{[5-(4-ETIL-1-PIPERAZINIL)IMIDAZO[1,2-a]PIRIDIN-2-IL]METIL}-N-METIL-5,6,7,8-TETRAHIDRO-8-QUINOLINAMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SE UNEN ESPECIFICAMENTE AL RECEPTOR DE QUIMIOQUINA, AFECTANDO LA UNION DEL LIGANDO NATURAL O LA QUIMIOQUINA A UN RECEPTOR, TAL COMO CXCR4 Y/O CCR5 DE UNA CELULA BLANCO Y SON UTILES POR SUS EFECTOS PROTECTORES SOBRE CELULAS DE BLANCO CONTRA INFECCION POR VIH
PE2005001007A 2004-09-02 2005-09-01 Compuestos derivados de quinolinamina como moduladores del receptor de quimioquina PE20060712A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60674204P 2004-09-02 2004-09-02
US61076504P 2004-09-17 2004-09-17

Publications (1)

Publication Number Publication Date
PE20060712A1 true PE20060712A1 (es) 2006-08-24

Family

ID=36000724

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2005001008A PE20060656A1 (es) 2004-09-02 2005-09-01 COMPUESTOS DE IMIDAZO[1,2-a]PIRIDINIL COMO MODULADORES DE LA ACTIVIDAD DE QUIMIOQUINAS
PE2005001007A PE20060712A1 (es) 2004-09-02 2005-09-01 Compuestos derivados de quinolinamina como moduladores del receptor de quimioquina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2005001008A PE20060656A1 (es) 2004-09-02 2005-09-01 COMPUESTOS DE IMIDAZO[1,2-a]PIRIDINIL COMO MODULADORES DE LA ACTIVIDAD DE QUIMIOQUINAS

Country Status (16)

Country Link
US (2) US20070232615A1 (es)
EP (2) EP1799671A4 (es)
JP (2) JP2008511669A (es)
KR (2) KR20070049682A (es)
AR (2) AR050302A1 (es)
AU (2) AU2005279835A1 (es)
BR (1) BRPI0514881A (es)
CA (2) CA2579059A1 (es)
IL (1) IL181419A0 (es)
MA (1) MA28872B1 (es)
MX (2) MX2007002679A (es)
NO (2) NO20071366L (es)
PE (2) PE20060656A1 (es)
RU (2) RU2352567C2 (es)
TW (2) TW200621754A (es)
WO (2) WO2006026703A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002679A (es) * 2004-09-02 2007-05-16 Smithkline Beecham Corp Compuestos quimicos.
PE20070946A1 (es) * 2006-01-25 2007-10-16 Smithkline Beecham Corp COMPUESTOS DERIVADOS DE IMIDAZO[1,2-a]PIRIDINA COMO MODULADORES DEL RECEPTOR DE QUIMIOQUINA (CXCR4)
JP5257068B2 (ja) 2006-05-16 2013-08-07 小野薬品工業株式会社 保護されていてもよい酸性基を含有する化合物およびその用途
US20090325992A1 (en) 2006-07-31 2009-12-31 Ono Pharmaceutical Co., Ltd. Compound having cyclic group bound thereto through spiro binding and use thereof
US7767826B2 (en) * 2007-10-05 2010-08-03 Pharmatech International, Inc. Process for the synthesis of L-(+)-ergothioneine
US20100292232A1 (en) * 2007-11-09 2010-11-18 Daniel Elleder Non-nucleoside reverse transcriptase inhibitors
CN102675305B (zh) * 2011-03-08 2014-11-12 中国科学院上海药物研究所 一类咪唑并吡啶类化合物及其制备方法和用途
CN103570683B (zh) * 2012-07-30 2018-04-17 中国科学院上海药物研究所 多取代胺类化合物及其制备方法和用途
RS59534B1 (sr) 2014-02-13 2019-12-31 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
PH12020552066A1 (en) 2014-02-13 2022-05-11 Incyte Corp Cyclopropylamines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EP3626720A1 (en) 2015-04-03 2020-03-25 Incyte Corporation Heterocyclic compounds as lsd1 inhibitors
MX389824B (es) 2015-08-12 2025-03-20 Incyte Holdings Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP6864296B2 (ja) 2015-12-14 2021-04-28 エックス４ ファーマシューティカルズ， インコーポレイテッド がんを処置する方法
KR102738306B1 (ko) * 2015-12-15 2024-12-03 브리스톨-마이어스 스큅 컴퍼니 Cxcr4 수용체 길항제
EP3393468B1 (en) 2015-12-22 2022-09-14 X4 Pharmaceuticals, Inc. Methods for treating immunodeficiency disease
WO2017177230A1 (en) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Methods for treating cancer
CA3027495A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CA3027498A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
IL309069A (en) * 2017-02-21 2024-02-01 Univ Emory CXCR4 cytokine receptor modulators and related uses
KR102678977B1 (ko) * 2017-09-25 2024-06-28 씨젠테크 (쑤저우, 차이나) 컴퍼니 리미티드 Cxcr4 저해제로서 헤테로아릴 화합물, 그 조성물 및 이용 방법
US11396501B2 (en) * 2017-09-25 2022-07-26 Cgenetech (Suzhou, China) Co., Ltd. Heteroaryl compounds as CXCR4 inhibitors, composition and method using the same
EP3768256A4 (en) 2018-03-19 2021-11-24 Emory University PANTROPIC ENTRY INHIBITORS
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN115515585A (zh) 2020-03-10 2022-12-23 X4 制药有限公司 用于治疗中性粒细胞减少症的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ225152A (en) * 1987-07-17 1990-04-26 Janssen Pharmaceutica Nv Heterocyclically substituted piperidinyl benzamides as pharmaceuticals
JP2004512336A (ja) * 2000-09-15 2004-04-22 アノーメッド　インコーポレイティド ケモカインレセプター結合複素環式化合物
SG126006A1 (en) * 2000-09-15 2006-10-30 Anormed Inc Chemokine receptor binding heterocyclic compounds
DE60137944D1 (de) * 2000-09-15 2009-04-23 Anormed Inc Chemokin rezeptor bindenden heterozyklische verbindungen
EP1752455B1 (en) * 2000-09-15 2010-11-10 Anormed Inc. Chemokine receptor binding heterocyclic compounds
CA2467718C (en) * 2001-12-21 2011-04-26 Anormed Inc. Chemokine receptor binding heterocyclic compounds with enhanced efficacy
EP1613613B1 (en) * 2003-04-11 2021-06-02 Genzyme Corporation Cxcr4 chemokine receptor binding compounds
MX2007002679A (es) * 2004-09-02 2007-05-16 Smithkline Beecham Corp Compuestos quimicos.
EP1793825A4 (en) * 2004-09-24 2009-12-09 Smithkline Beecham Corp CHEMICAL COMPOUNDS
US20080234318A1 (en) * 2005-08-31 2008-09-25 Kristjan Gudmundsson Chemical Compounds

Also Published As

Publication number Publication date
US20070254910A1 (en) 2007-11-01
AR050302A1 (es) 2006-10-11
KR20070049682A (ko) 2007-05-11
EP1799671A2 (en) 2007-06-27
RU2007106779A (ru) 2008-10-10
JP2008511668A (ja) 2008-04-17
MA28872B1 (fr) 2007-09-03
NO20071418L (no) 2007-05-31
CA2579059A1 (en) 2006-03-16
WO2006026703A8 (en) 2006-05-26
TW200612921A (en) 2006-05-01
IL181419A0 (en) 2007-07-04
KR20070053313A (ko) 2007-05-23
EP1784185A4 (en) 2009-06-03
TW200621754A (en) 2006-07-01
AR051565A1 (es) 2007-01-24
JP2008511669A (ja) 2008-04-17
CA2578746A1 (en) 2006-03-09
WO2006026703A2 (en) 2006-03-09
AU2005282753A1 (en) 2006-03-16
MX2007002615A (es) 2007-04-27
AU2005279835A1 (en) 2006-03-09
WO2006026703A3 (en) 2006-10-05
US20070232615A1 (en) 2007-10-04
BRPI0514881A (pt) 2008-06-24
RU2352567C2 (ru) 2009-04-20
MX2007002679A (es) 2007-05-16
RU2007106780A (ru) 2008-10-10
NO20071366L (no) 2007-05-31
PE20060656A1 (es) 2006-08-24
EP1784185A2 (en) 2007-05-16
EP1799671A4 (en) 2009-06-10
WO2006028896A3 (en) 2006-04-27
WO2006028896A2 (en) 2006-03-16
RU2351592C2 (ru) 2009-04-10

Similar Documents

Publication Publication Date Title
PE20060712A1 (es) Compuestos derivados de quinolinamina como moduladores del receptor de quimioquina
PE20040071A1 (es) Indazoles substituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion
PE20201448A1 (es) Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
AP1789A (en) Tropane derivatives useful in therapy.
PE20030471A1 (es) Compuesto de imidazopiridin como moduladores del receptor 5-ht4
NO20073729L (no) Heterocykliske forbindelser som CCR2B-antagonister
PE20011371A1 (es) Derivados de 3-(3-isopropil-5-metil-4h-1,2,4-triazol-4-il)-exo-8-azabiciclo[3.2.1]octano como antagonistas de los receptores de quimiocina ccr5
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
AR076838A1 (es) Sulfonamidas nematocidas
AR005044A1 (es) Compuesto benzazepina, procedimiento para preparar dicho compuesto benzazepina opticamente activo y un compuesto benzazepina útil como intermediario para su preparacion, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
MXPA05005660A (es) Derivados de 3-aminopirrolidina como moduladores de receptores de quimocina.
HUP0203458A2 (hu) Nociceptin ORL-1 receptor agonisták alkalmazása köhögés kezelésére és ezeket tartalmazó gyógyszerkészítmények
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
PE20060316A1 (es) Derivados de prolina como inhibidores de dipeptidil peptidasa-iv
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
IN2012DN00571A (es)
AR048642A1 (es) Compuestos de metil-aril o heteroaril-amida sustituida utiles como antagonistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
PE20091818A1 (es) DERIVADOS POLISUSTITUIDOS DE 2-ARIL-6-FENIL-IMIDAZO[1,2-a] PIRIDINAS, SU PREPARACION Y SU APLICACION EN TERAPEUTICA
DK1501507T3 (da) Tetrahydropyranyl-cyclopentyl-tertrahydropyridopyrindin-modulatorer af kemokin-receptor-aktivitet
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
AR039489A1 (es) Derivados de tetrahidropiranil ciclopentil tetrahidropiridopiridina, moduladores de actividad de receptores de citoquinas
ES2173846T3 (es) Compuestos de biciclocarbonil indol como agentes antiinflamatorios/analgesicos y como inhibidores de cox-2.
AR066103A1 (es) Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
AE Restoration of lapsed or forfeited application
FG Grant, registration
FD Application declared void or lapsed